ASH 2023 | Retrospective real-world study evaluating compassionate use of ponatinib in R/R Ph-like ALL
In this video, Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, discusses the results of a retrospective real-world study evaluating the safety and efficacy of ponatinib for patients with relapsed/refractory (R/R) Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL). Dr Chiaretti indicates that compassionate use of ponatinib resulted in a promising response rate and allowed patients to be bridged to allogeneic stem cell transplantation (alloSCT) or CAR T-cell therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Gilead: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Membership on an entity’s Board of Directors or advisory committees; Amgen: Membership on an entity’s Board of Directors or advisory committees.
